In addition to ipilimumab, nivolumab, and pembrolizumab, cemiplimab, an antibody against PD-1, and avelumab, atezolizumab, and durvalumab, antibodies against program death ligand 1 (PD-L1), are currently approved by the FDA, and the indications of ICIs for cancer therapy have been expanding (Table 1) (13). This evidence concerns the gene CD274 and cancer.